Advertisement Pharmaceutical Business review - Page 19 of 5226 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
November 27, 2024

Valneva submits application seeking FDA approval for IXCHIQ for adolescent use

Valneva has submitted an application to the US Food and Drug Administration (FDA) seeking approval for a label extension of its chikungunya vaccine, IXCHIQ.

IXCHIQ is a chikungunya vaccine, which was launched in the US in early March 2024. Credit: National Institute of Allergy and Infectious Diseases on Unsplash.